Poster Session 2

Presentation numberPS2-01-01

Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Capsular Contracture after Nipple-Sparing Mastectomy with Implant-Based Breast Reconstruction

Jongwon Kang, Seoul national university bundang hospital, Seongnam, Korea, Republic of

Presentation numberPS2-01-02

Magnetic seed for preoperative localization of non‑palpable breast cancer: impact on care pathway organization and re-excision rate

Delphine Hequet, Institut Bourdonnais, Paris, France

Presentation numberPS2-01-03

Is Breast Conserving Surgery a Viable Option for Non-Inflammatory T3/T4 Breast Cancer?

Leena Almaghrabi, KFSHD, Dammam, Saudi Arabia

Presentation numberPS2-01-04

Association of Long-term Oncologic Prognosis With Internal Mammary Sentinel Lymph Node Biopsy In Breast Cancer Patients

Pengfei Qiu, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

Presentation numberPS2-01-05

Improving radical resection rates in patients with breast cancer by intraoperative imaging using bevacizumab-IRDye800CW – the MARGIN-2 study

Joni J. Nijveldt, University Medical Center Groningen, Groningen, Netherlands

Presentation numberPS2-01-07

A Multicenter Retrospective Observational Study on the Safety and Timing of Radiotherapy After Oncoplastic Breast-Conserving Surgery

Rena Yamakado, Mie medical University, Tsu, Japan

Presentation numberPS2-01-08

A Decade Later: Our Updated Systematic Review and Meta-Analysis of Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence Following Nipple-Sparing Mastectomy

Rachel N Rohrich, Medstar Georgetown University Hospital, Washington, DC

Presentation numberPS2-01-09

The Structural Mastectomy: Application of circum-mammary ligament preservation in nipple-sparing mastectomy

Rachel N Rohrich, Medstar Georgetown University Hospital, Washington, DC

Presentation numberPS2-01-10

De-escalation of sentinel lymph node biopsy beyond the Choosing Wisely guidelines

Tiffany Cheung, Cleveland Clinic, Cleveland, OH

Presentation numberPS2-01-11

Cumulative Medical Costs of Prepectoral versus Subpectoral Implant-Based Breast Reconstruction: A Retrospective Analysis of a Single Academic Center

David B Lipps, University of Michigan, Ann Arbor, MI

Presentation numberPS2-01-12

Evaluation of different methods of targeting axillary lymph node for axillary surgery in patients with clinically node-positive breast cancer: A retrospective multicenter study

Cho Eun Lee, Samsung Medical Center, Seoul, Korea, Republic of

Presentation numberPS2-01-13

Pixels to Prognosis: Predicting Response to NAST Using Multiparametric Imaging Combining Tomosynthesis, Shear Wave Elastography and Doppler

Gaurav Agarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, Lucknow, India

Presentation numberPS2-01-14

Omission of sentinel lymph node biopsy among women age 50-70: applying updated ASCO guidelines to a real-world population

Meghan R Flanagan, University of Washington, Seattle, WA

Presentation numberPS2-01-15

Long-term outcomes of sentinel lymph node biopsy alone for breast cancer with residual axillary nodal disease (ypN+) following neoadjuvant chemotherapy: a systematic review and meta-analysis.

Mariam Rana, University of Saskatchewan, Regina, SK, Canada

Presentation numberPS2-01-16

Feasibility of Systematic Breast-Conserving Surgery Under Local Anesthesia and Sedation: A Large Single-Center Study

Delphine Hequet, Institut Bourdonnais, Paris, France

Presentation numberPS2-01-17

Long term outcome of patients having Breast Conserving Surgery and Immediate Lipofilling

James Lucocq, Western General Hospital, Edinburgh, United Kingdom

Presentation numberPS2-01-18

Targeted Axillary Dissection after Neoadjuvant Systemic Chemotherapy in patients with Early Breast Cancer: Estimating the Real-World Impact of Omitted Axillary Lymph Node Dissection using the Canto Cohort

Angelica Conversano, GUSTAVE ROUSSY, Villejuif, France

Presentation numberPS2-01-20

Unexpected invasive breast cancer after mastectomy for in situ carcinoma and implication on axillary management – data from a real-world collective

Elna Kuehnle, Hannover Medical School, Hannover, Germany

Presentation numberPS2-01-21

Risk Factors for Fat Necrosis Following Abdominally Based Autologous Breast Reconstruction

Michael Choi, University of California, San Francisco, San Francisco, CA

Presentation numberPS2-01-22

Changes in reoperation rate after publication of guidelines defined positive margins for breast conserving surgery: Collaboration study of Japanese Breast Cancer Society

Takehiko Sakai, Cancer Institute Hospital of JFCR, Tokyo, Japan

Presentation numberPS2-01-23

The accuracy of sentinel lymph node biopsy in locally advanced breast cancer

Alexander Petrovsky, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

Presentation numberPS2-01-24

Efficacy and safety of intercostal nerve anastomosis in immediate biplane breast reconstruction after nipple-areola-sparing mastectomy: a randomized, controlled, open-label clinical study

Zhang Juan, Tangshan People's Hospital, Tangshan, China

Presentation numberPS2-01-25

Does surgery in a specialized clinic improve locoregional recurrence rates in Inflammatory Breast Cancer?

Vanessa N. Sarli, UT MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-01-27

A retrospective cohort study on axilla management in ipsilateral breast tumor recurrence after partial mastectomy with sentinel node biopsy

Takahiro Nakayama, Osaka International Cancer Institute, Osaka, Japan

Presentation numberPS2-01-28

Factors influencing surgical decision-making in breast cancer using patient-reported outcomes- A multicenter collaborative study-

Hirohito Seki, Kyorin University School of Medicine, Tokyo, Japan

Presentation numberPS2-01-29

Post-operative complications of breast cancer surgery among women with and without obesity in the U.S. Military Health System

Brooke A. Engelman, Landstuhl Regional Medical Center, Landstuhl, Germany

Presentation numberPS2-01-30

Patients with small, clinically and imaging node-negative, HR-positive/HER2-negative early breast cancer undergoing mastectomy do not show increased node-positivity and missed adjuvant systemic treatment options

Martin Heidinger, University Hospital Basel, Basel, Switzerland

Presentation numberPS2-03-01

Nipple Delay Improves Nipple-Areolar Complex Viability in High-Risk NSM Patients

Koshi Matsui, University of Toyama, Toyama, Japan

Presentation numberPS2-03-02

Breast surgery for metastatic breast cancer a update of Cochrane systematic review

Giuliano Tosello, Unoeste, Presidente Prudente, Brazil

Presentation numberPS2-03-03

Retrospective analysis of axillary recurrence in patients with breast cancer receiving radiotherapy to the axillary after positive sentinel lymph node biopsy

Chandana Gavisiddappa, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom

Presentation numberPS2-03-04

Re-defining Breast Cancer care in an LMIC- a single center study on long term oncological and cosmetic outcomes of Oncoplastic Breast Surgery

Safna Naozer Virji, Aga Khan University Hospital, Karachi, Karachi, Pakistan

Presentation numberPS2-03-05

Evaluating the Role of Preoperative Magnetic Resonance Imaging and Intraoperative 3D Tomosynthesis in Achieving Negative Resection Margins in DCIS

STYLIANI PARPOUDI, Anticancer Hospital Theageneio, Thessaloniki, Greece

Presentation numberPS2-03-06

Prevalence and Impact of Treatment-Related Pain on Quality of Life in Brazilian Breast Cancer Patients

Rosemar Macedo Sousa Rahal, UNIVERSIDADE FEDERAL DE GOIAS, Goiania, Brazil

Presentation numberPS2-03-07

Oncoplastic and Reconstructive Breast Surgery: Experience in a Public Healthcare Center of the Brazilian Unified Health System (SUS)

Carolina Souza Vasconcelos, Hospital Cancer of Pernambuco, Recife, Brazil

Presentation numberPS2-03-08

Survival outcomes after lumpectomy versus therapeutic mammoplasty in breast cancer patients: a Brazilian cohort study

Anne Dominique Nascimento Lima, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Presentation numberPS2-03-09

Is it safe to offer breast-conserving surgery after neoadjuvant chemotherapy? A Brazilian multicenter cohort study

Anne Dominique Nascimento Lima, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Presentation numberPS2-03-10

Safety of nipple/skin-sparing mastectomy in breast cancer patients who had breast implants

Seongjin Jeong, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

Presentation numberPS2-03-11

Current Practices and Perspectives in the Management of Multicentric and Multifocal Breast Cancer: A Survey-Based Analysis

Revathy Krishnamurthy, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India

Presentation numberPS2-03-12

Impact of non-sequential lymphatic spread on breast cancer prognosis

Pinxuan Zhu, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Presentation numberPS2-03-13

Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study.

Nadia Bianco, European Institute of Oncology, IRCCS, Milan, Italy

Presentation numberPS2-03-14

Autologous versus Implant-Based Breast Reconstruction: Complication and corrective surgery rates with and without Radiotherapy

Romi Cencelj-Arnez, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Presentation numberPS2-03-15

Breast Sensitization Techniques in Mastectomies with An Implant-Based Reconstruction: A Systematic Review

Jasmine El-Taraboulsi, Imperial College Healthcare NHS Trust, London, United Kingdom

Presentation numberPS2-03-16

Endoscopic Nipple Sparing Mastectomy: Early Outcomes and Learning Curve from a Unicentric Series of 21 Cases

Julien Seror, Institut Bourdonnais, Paris, France

Presentation numberPS2-03-17

Dose reductions in metastatic breast cancer patients: Frequency, strategies, and patient experience

Amy Beumer, Patient Centered Dosing Initiative, Denver, CO

Presentation numberPS2-03-18

Postoperative cavity remodeling technique in breast-conserving surgery: a case series

Yuxia Chen, Maoming People's Hospital, Maoming, China

Presentation numberPS2-03-19

Foreseeing Fluid: Risk Factors for Seroma Formation Following Skin- and Nipple-Sparing Mastectomy with Immediate Reconstruction.

Kerstin Pfister, University Hospital Ulm, Ulm, Germany

Presentation numberPS2-03-20

Feasibility of the omission of axillary surgery in node-negative early breast cancer: a systematic review and meta-analysis

James Lucocq, Western General Hospital, Edinburgh, United Kingdom

Presentation numberPS2-03-21

Trends in axillary surgical strategies for breast cancer patients with clinical complete response after neoadjuvant systemic therapy: a population-based retrospective cohort study

Yizi Zheng, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Presentation numberPS2-03-22

Retromamamry breast-conserving surgery and volume displacement with diced acellular dermal matrix for operable breast cancer

Jean Schneider, Texas Tech University Health Sciences Center, Lubbock, TX

Presentation numberPS2-03-23

What really drives seroma formation? – Insights from a retrospective study of 244 patients undergoing mastectomy.

Laura Weydandt, University hospital Leipzig, Leipzig, Germany

Presentation numberPS2-03-24

De-escalation of Axillary Surgery in Patients with Residual Nodal Disease After Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis

Natalia Polidorio, Rede Americas Oncology, São Paulo, Brazil

Presentation numberPS2-03-25

Serratus anterior fascia flap versus muscle flap for implant coverage in immediate subpectoral breast reconstruction

Lilian de Sá Paz, Aristides Maltez Hospital; Oncoclínicas&Co –Medica Scientia Innovation Research (MEDSIR), Salvador, Brazil

Presentation numberPS2-03-26

Lymphatic-sparing sentinel lymph node biopsy to prevent breast cancer-related lymphedema

Eleni Kohilakis, Montefiore Medical Center, Bronx, NY

Presentation numberPS2-03-27

Comparison of Robot-assisted and Conventional Partial Mastectomy in Breast Cancer Patients: A Pilot Study

Si Yeon Lee, Yonsei University College of Medicine, Seoul, Korea, Republic of

Presentation numberPS2-03-28

An Investigation to Identify the Factors for Negative Sentinel Lymph Node in Early Breast Cancer Cases

Reiki Nishimura, Fukuda Hospital, Kumamoto City, Japan

Presentation numberPS2-03-29

Evaluating Prognosis According to Axillary Surgery in Breast Cancer Patients with Isolated Internal Mammary Lymph Node Metastasis (cN2b): A Retrospective Cohort Study

Yoshiharu Ishizaka, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Presentation numberPS2-03-30

Age at breast cancer diagnosis and short-term postoperative outcomes for women treated in a universal-coverage health system

Gabrielle Falco, San Antonio Military Medical Center, Fort Sam Houston, TX

Presentation numberPS2-05-01

Pro-tigr-matrix-prepectoral-trial

Marc Antonius Maria Thill, Agaplesion Markus Krankenhaus, Frankfurt, Germany

Presentation numberPS2-05-03

Lateral intercostal artery perforator (LICAP) flap: a new surgical approach for granulomatous lobular mastitis

Wei-xian Chen, Changzhou No.2 People's Hospital, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

Presentation numberPS2-05-04

Single-dye sentinel lymph node mapping for targeted axillary dissection in breast cancer patients after neoadjuvant chemotherapy: a prospective study

Wuzhen Chen, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Presentation numberPS2-05-05

The Anatomic Basis of Thoracodorsal Artery Perforator-based Flap: Cadaveric and Angiographic Study

Ramita Mukherjee, All India Institute of Medical Sciences, New Delhi, Delhi, India

Presentation numberPS2-05-06

Safety and Oncologic Outcomes of Immediate Breast Reconstruction Following Neoadjuvant Chemotherapy

Mai Tomiguchi, Kumamoto University Hospital, KUMAMOTO, Japan

Presentation numberPS2-05-07

Evaluation of fusion imaging guidance in radiofrequency ablation for early-stage breast cancer

CHIE YAMANAKA, Kindai University, Osaka, Japan

Presentation numberPS2-05-08

Refusal of sentinel lymph node biopsy in patients with luminal A subtype early breast cancer

Petr Vladimirivich Krivorotko, FSBI “N.N. Petrov National Medical Research Center of Oncology” of the Russian Ministry of Health, Saint Petersburg, Russian Federation

Presentation numberPS2-05-09

Preoperative Assessment for the Omission of Sentinel Node Biopsy in Luminal/HER2-Negative Breast Cancer in Low-Resource Settings

Julia Dias do Prado, Hospital Universitário Antônio Pedro (HUAP-UFF), Niterói, Brazil

Presentation numberPS2-05-10

Comparative microbiome analysis of biofilm in contracted breast capsules: a cross-sectional study

Yang Jung Dug, School of Medicine, Kyungpook National University, Daegu, Korea, Republic of

Presentation numberPS2-05-11

Early oncologic outcomes of robot-assisted versus conventional nipple-sparing mastectomy: a propensity score matching analysis

Seung Ah Lee, Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of

Presentation numberPS2-05-16

Prognostic value of TILs variation in breast cancer undergoing neoadjuvant chemotherapy

Alessandra Amatuzzi Fornazari, Hospital de Clínicas, Curitiba, Brazil

Presentation numberPS2-05-17

Pathologic response in invasive lobular carcinoma versus invasive ductal carcinoma following neoadjuvant therapy: A single institution study

Tristan Jordan, Yale New Haven Hospital, New Haven, CT

Presentation numberPS2-05-18

Distinct Biological Profiles of Mucinous Carcinoma with a Solid Papillary Carcinoma Component Compared to Other Histological Types

Yuki Hara, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Presentation numberPS2-05-19

Immuno- and Molecular-Profiling of Breast Cancer Metastasis in the CNS

Niklas Abele, University Erlangen, Erlangen, Germany

Presentation numberPS2-05-20

Evaluation of novel diagnostic kits for detecting metastatic lymph nodes in breast cancer patients treated with neoadjuvant chemotherapy using the semi-dry dot-blot method: A single-center prospective study

Ryota Otsubo, Nagasaki University Hospital, Nagasaki, Japan

Presentation numberPS2-05-21

Altered expression of catenins and cadherins in lobular breast cancer: A focus on beta-catenin and E-cadherin

Taesung Jeon, Korea University Guro Hospital, Seoul, Korea, Republic of

Presentation numberPS2-05-22

Assessment of the tumor bed area in patients with breast cancer and RCB class I after neoadjuvant therapy: comparison of original and modified method.

Nikolay Amirov, NMRC of Oncology named after N.N. Petrov, Saint Petersburg, Russian Federation

Presentation numberPS2-05-23

Immune Heterogeneity in Breast Cancer Natural History: Benign Breast Disease to Breast Cancer

Amy Zhang, UNC Medical School, Chapel Hill, NC

Presentation numberPS2-05-24

Histopathological Grade as a Prognostic Marker in de novo Metastatic HER2-Positive Breast Cancer Treated with First-Line Docetaxel, Trastuzumab, and Pertuzumab

Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

Presentation numberPS2-05-25

Slide-free histology for breast cancer core-needle-biopsy diagnostics at point-of care in Ghana

Richard Levenson, UC Davis Health, Sacramento, CA

Presentation numberPS2-05-26

Analytical performance of an image analysis algorithm developed as an adjunctive aid for determining HER2 gene status from in situ hybridization

Keith A Wharton Jr, Roche Diagnostics Ltd, Boston, MA

Presentation numberPS2-02-01

Improved Antiemetic Outcomes with NEPA vs (Fos)aprepitant in Patients with Breast Cancer Receiving Antibody-Drug Conjugates: A 12-Month Real-World Claims Analysis

Lee S. Schwartzberg, Renown Health, Reno, NV

Presentation numberPS2-02-02

Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in breast cancer patients: an international retrospective cohort study

Luca Visani, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

Presentation numberPS2-02-03

Real-world treatment patterns in 1954 US patients with HER2-negative early breast cancer and germline BRCA mutations (2021-2025)

Sagar Sardesai, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Presentation numberPS2-02-04

Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024

Jane L Meisel, Winship Canter Institute of Emory University, Atlanta, GA

Presentation numberPS2-02-05

Ibc clear: a decentralized multi-center mrd registry for inflammatory breast cancer

Angela Alexander, University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-02-06

Benefit of adjuvant chemotherapy for early-stage hormone receptor positive and HER2 negative lobular breast cancer patients: Analysis based on genomic risk scores

Arya Mariam Roy, The Ohio State University, Columbus, OH

Presentation numberPS2-02-07

Impact of BRCA homozygous copy loss on clinical outcomes of patients (pts) with metastatic breast cancer (MBC) treated with PARP inhibitors (PARPi)

Adela Rodríguez-Hernández, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS2-02-08

Real-world PARP inhibitor use and clinical outcomes in US patients with HER2-negative metastatic breast cancer

Siddhartha Yadav, Mayo Clinic, Rochester, MN

Presentation numberPS2-02-09

Fr-pop: Real-world data from 7,687 high-risk TNBC patients treated with perioperative pembrolizumab in France

Olivier Tredan, Centre Leon Berard, Cancer Research Center of Lyon (UMR Inserm 1052 – CNRS 5286), Lyon, France

Presentation numberPS2-02-10

The Benefit and Burden of Adjuvant Endocrine Therapy for Older Individuals with Early Stage, Hormone Receptor Positive Breast Cancer

Danielle Rodin, Princess Margaret Cancer Centre, Toronto, ON, Canada

Presentation numberPS2-02-11

Impact of discordance between the 70-gene and 21-gene genomic assays on breast cancer treatment planning and outcomes 

Adam Brufsky, University of Pittsburgh, Pittsburgh, PA

Presentation numberPS2-02-12

Tolerability of Adjuvant Abemaciclib in Older Adults with High-Risk Early Breast Cancer: Multicentre UK Real-World Data from the CONCISE Study

Olubukola Ayodele, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Presentation numberPS2-02-13

Bridging Diagnostic Gaps in LMICs- Real-World Functionality of a One-Stop Breast Centre in South India

Debashri Shankarraman, Chennai Breast Centre, Chennai, India

Presentation numberPS2-02-14

Improving Identification and Enrollment in HR+/HER2− Breast Cancer Trials Using AI Clinical Trial Patient Matching Tool

Guannan Gong, Yale School of Medicine, New Haven, CT

Presentation numberPS2-02-15

The impact of ASCO/CCO guidelines on the use of adjuvant bone-modifying agents by specialized and general oncologists for elderly patients with breast cancer

Jennifer Caswell-Jin, Stanford University, Stanford, CA

Presentation numberPS2-02-16

Can NHS PREDICT Guide Oncotype DX Use in ER+/HER2− Early Breast Cancer: A Multicentre Analysis

Sanjit Kumar Agrawal, Tata Medical Center, kolkata, India

Presentation numberPS2-02-17

The High Unmet Need of Patients with Early Relapse After the KEYNOTE-522 Regimen – Evidence from the Neo-Real/GBECAM-0123 Study

Renata Colombo Bonadio, Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil

Presentation numberPS2-02-18

Real-world epidemiologic and biological characterisation of breast cancer in Algeria: A multicenter real world data study on 6044 patients

Adda Bounedjar, University of Blida 1, Blida, Algeria

Presentation numberPS2-02-19

Trends and Disparities in Heart Failure Mortality Among US Adult Females with Breast Cancer from 1999 to 2020: A 22-Year Retrospective Study

Mercy C Anyanwu, Icahn School of Medicine at Mount Sinai, New York, NY

Presentation numberPS2-02-20

Treatment patterns and clinical outcomes following progression on first-line ET + CDK4/6i among patients with HR+/HER2− metastatic breast cancer (mBC) in the US

Virginia Kaklamani, UT Health San Antonio, San Antonio, TX

Presentation numberPS2-02-21

Real-world outcomes of CDK4/6 inhibitors in patients with metastatic invasive lobular carcinoma: a retrospective single-center study

Anastasia Danilova, Moscow City Oncology Hospital 62, Stepanovskoe, Russian Federation

Presentation numberPS2-02-22

Impact of Body Mass Index on the Efficacy and Safety of Adjuvant Abemaciclib in a Real-World Brazilian Cohort of Patients With High-Risk Early Breast Cancer

Monique Celeleste Tavares, Hospital A.C Camargo Cancer Center, São Paulo, Brazil

Presentation numberPS2-02-23

Clinicopathological profile and outcomes in young Indian patients with breast cancer – A single-center experience

Tanay Shah, HCG Aastha Cancer Center, Ahmedabad, India

Presentation numberPS2-02-24

Comparative Effects of Semaglutide vs Tirzepatide on Weight Change and Cardiovascular Risk in Breast Cancer Survivors

Jasmin Hundal, Cleveland Clinic, Clevelan, OH

Presentation numberPS2-02-25

Centering the Patient Experience within TNBC Care and Fostering Equity in the Hispanic and Latina Populations​

Tariqa Ackbarali, Medlive, Lake Worth, MA

Presentation numberPS2-02-26

Treatment patterns and prognosis of patients with HER2-negative early breast cancer and germline pathogenic variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2

Vishnu Prasath, The Ohio State University College of Medicine, Columbus, OH

Presentation numberPS2-02-27

Validation of a Novel Prognostic Staging System for Breast Cancer Incorporating Age at Diagnosis

Helen M Johnson, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-02-28

Prognostic Value of a Machine Learning Tool for Recurrence Risk Stratification in HR+/HER2- Early Breast Cancer: A Brazilian Cohort Analysis

Rubem Moreira, Instituto Nacional de Cancer, Rio de Janeiro, Brazil

Presentation numberPS2-02-29

Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia – ARORA Registry

Michelle Li, Walter Eliza Hall Institute of Medical Research, Victoria, Australia

Presentation numberPS2-02-30

Five-year survival outcomes after systemic therapy in older patients with early-stage triple negative breast cancer at memorial sloan kettering cancer center.

Jasmeet Singh, Memorial Sloan Kettering, New York, NY

Presentation numberPS2-04-02

Real-world evidence of immunohistochemical discordance in breast cancer brain metastases

Jessé Silva, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Presentation numberPS2-04-03

Herpes zoster vaccination and risk of breast cancer in women undergoing mammographic screening: a trinetx real-world analysis

Olga Serra, IRST IRCCS Dino Amadori, Meldola, Italy

Presentation numberPS2-04-04

First Real-World Evidence Linking Anxiety to Poorer Treatment Response and Survival in Early-Stage Breast Cancer

Yulong Chen, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, China

Presentation numberPS2-04-05

Long-term outcomes and toxicities of doxorubicin-cyclophosphamide chemotherapy in breast cancer: a McGill University Health Centre experience, 100-month interim analysis

Eliana Rohr, McGill University, Montréal, QC, Canada

Presentation numberPS2-04-06

Real-world outcomes of trastuzumab deruxtecan with or without endocrine therapy in her2-low, hormone receptor-positive metastatic breast cancer: a propensity-matched analysis

Michela Palleschi, IRST IRCCS Dino Amadori, Meldola, Italy

Presentation numberPS2-04-07

A large-scale, US-based study evaluating real-world medical cost savings and reduced healthcare resource utilization associated with longer first-line treatment for advanced breast cancer

Clara Chen, AstraZeneca, Gaithersburg, MD

Presentation numberPS2-04-08

Incidence of second primary tumors and second primary breast cancers events in patients with metastatic breast cancer: results from the Austrian AGMT_MBC-Registry

Vanessa Castagnaviz, Paracelsus Medical University Salzburg, Salzburg, Austria

Presentation numberPS2-04-09

Impact of prior treatment exposure and clinical-pathological factors on response and survival with Sacituzumab govitecan in advanced breast cancer: a consecutive real-world series

Carla Gullotta, Hospital Clinic Barcelona, Barcelona, Spain

Presentation numberPS2-04-10

Adherence to endocrine prevention in patients with atypical hyperplasia and lobular carcinoma in situ: promising trends from real-world use of low dose tamoxifen.

Natasha Stonebanks Cuillerier, Jewish General Hospital, Montreal, QC, Canada

Presentation numberPS2-04-11

Treatment Sequencing in HR+ HER2- Metastatic Breast Cancer and Associated Real World Outcomes

Nicholas P McAndrew, UCLA, Santa Monica, CA

Presentation numberPS2-04-12

Real-world overall survival with palbociclib plus an aromatase inhibitor (AI) in patients with HR+/HER2− metastatic breast cancer (MBC) who are overweight/obese

Adam Brufsky, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA

Presentation numberPS2-04-13

Treatment Outcomes Among African American and Non-Hispanic White Breast Cancer Patients Treated with KEYNOTE-522

La-Urshalar Brock, Winship Cancer Institute at Emory University and Nell Hodgson Woodruff School of Nursing, Atlanta, GA

Presentation numberPS2-04-14

Safety of Ribociclib for patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer: the Royal Marsden experience

Abigail Pomeranc, Royal Marsden Hospital, London, United Kingdom

Presentation numberPS2-04-15

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from a central European cohort

Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

Presentation numberPS2-04-16

Single institution retrospective analysis of antibody-drug conjugate (ADC) sequencing in HR+/HER2-low and HR-/HER2-low metastatic breast cancer.

Austin Kordic, City of Hope, Duarte, CA

Presentation numberPS2-04-17

Clinical and pathological characteristics of early hormone receptor-positive, HER2 negative breast cancer patients in Panama

Cristiane Martin, Instituto Oncológico Nacional, panama, Panama

Presentation numberPS2-04-18

Long-term safety in breast cancer patients receiving doxorubicin-cyclophosphamide chemotherapy with secondary G-CSF prophylaxis: A single-centre prospective study

Eliana Rohr, McGill University, Montréal, QC, Canada

Presentation numberPS2-04-19

10-year survival outcomes of early-staged breast cancer patients with intermediate- and high- risk hormone receptor-positive her2-negative disease

Winnie Yeo, Chinese University of Hong Kong, Hong Kong, Hong Kong

Presentation numberPS2-04-20

Real-world efficacy of everolimus in ER+/HER2- metastatic breast cancer following CDK4/6 inhibitors: a multicenter registry-based study

Hikari Kiyohara, Tokai University School of Medicine, Isehara, Japan

Presentation numberPS2-04-21

Impact of Pre-Neoadjuvant Radioactive Iodine Seed Marking on Pathological Complete Response and Survival in Breast Cancer Patients

Yihao Geng, Shandong Provincial Tumor Hospital, Shan Dong, China

Presentation numberPS2-04-22

Real world data of primary resistance to cyclin-dependent kinase 4/6 inhibitors treatment in hormone-receptor positive metastatic breast cancer

Ona Cano i Cano, Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain

Presentation numberPS2-04-23

Poor response to systemic therapy upon progression on cyclin dependent kinase 4/6 inhibitors in HR+ Inflammatory Breast Cancer

Azadeh Nasrazadani, MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-04-25

Efficacy of maintenance endocrine therapy combined with trastuzumab + pertuzumab following taxane induction in HR+/HER2+ metastatic breast cancer: A real-world reproduction of the PATINA trial control arm.

Laurent Mathiot, Institut de Cancérologie de l'Ouest, Saint-Herblain, France

Presentation numberPS2-04-26

A comparison of clinical features and treatment outcomes in breast cancer leptomeningeal metastasis between African American and Caucasian populations: a single institution experience

Bipin Ghimire, Henry Ford Health, Detroit, MI

Presentation numberPS2-04-27

Real-world Clinical Outcomes of Trastuzumab Deruxtecan Among HER2+ Metastatic Breast Cancer Patients with and without Brain Metastases: Data from U.S Community Oncology Practices

Sibel Blau, ONCare Alliance, Tacoma, WA

Presentation numberPS2-04-28

Symptom trajectories using remote symptom monitoring across treatment type and stage

Jeffrey A Franks, University of Alabama at Birmingham, Birmingham, AL

Presentation numberPS2-04-29

Parp inhibitors use in patients in germline palb2 or somatic brca1/2 mutations carriers with metastatic breast cancer: real life data from the esme database

Pauline ROTTIER, Centre François Baclesse, Caen, France

Presentation numberPS2-04-30

Enrolment of Patients with Metastatic Lobular Breast Cancer in Clinical Trials in the Multicenter ESME Cohort

Eleonora De Maio, IUCT ONCOPOLE, Toulouse Cedex 9, France

Presentation numberPS2-06-01

Real World Outcomes of the Keynote 522 Regimen for Triple-Negative Breast Cancer

Katherine E Myers, Case Western Reserve University/University Hospitals, Cleveland, OH

Presentation numberPS2-06-02

Real-world outcomes comparing zoledronic acid and pamidronate in patients with metastatic breast cancer with bone metastases: A propensity score matched analysis from a global federated health research network

Yajur Arya, Mayo Clinic, Jacksonville, FL

Presentation numberPS2-06-03

Sacituzumab Govitecan Dosing and Neutropenia Risk in Patients with HER2-Negative Metastatic Breast Cancer

Alexandra Bili Newman, MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-06-04

Invasive lobular breast cancer: Ten-year follow-up data from a single center

Ivica Ratosa, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Presentation numberPS2-06-06

Real-world utilization of tissue-free ctDNA monitoring in patients with breast cancer

Douglas K Marks, NYU Langone Health, Mineola, NY

Presentation numberPS2-06-08

Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-low metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program

Christine Brezden-Masley, Mount Sinai Hospital, Toronto, ON, Canada

Presentation numberPS2-06-09

Vacuum-assisted biopsy in the era of low-risk ductal carcinoma in situ active monitoring: real world data and implications.

Henrique Lima Couto, Redimama-Redimasto, Belo Horizonte, Brazil

Presentation numberPS2-06-10

Pathologic Complete Response by Breast Cancer Molecular Subtype in a Colombian Cohort: Real-World Evidence from Latin America

Monica A Solis Velasco, Universidad del Valle, Cali, Colombia

Presentation numberPS2-06-11

Real World Experience of PIK3CA, AKT inhibitors, and oral SERD in patients with hormone receptor positive metastatic breast cancer

Yeonjoo Choi, Cedars-Sinai Medical Center, Los Angeles, CA

Presentation numberPS2-06-12

Quantifying the Minimum Acceptable Benefit for a Novel Oral Adjuvant Therapy in HR+/HER2− Early Breast Cancer: A Probabilistic Threshold Technique Study in Italy

Ilaria Viganò, Novartis Farma S.P.A., Milan, Italy

Presentation numberPS2-06-13

Implementation of Liquid Biopsy in a Real-World Clinical Setting: Guiding Treatment Decisions in Metastatic Breast Cancer through Genomic Profiling

Alvaro Garcia-Bauto, Institut Català d'Oncologia, Barcelona, Spain

Presentation numberPS2-06-14

Breast Cancer (BC) in Younger Women: A Multicentre Cohort Study of Clinical and Pathological Features

Karen Desouza, University College London Hospital NHS, London, United Kingdom

Presentation numberPS2-06-15

Population-based outcomes and patterns of care for patients with stage I-III, HER2-negative breast cancer, by estrogen receptor expression levels: a high-resolution study.

Fabio Girardi, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Presentation numberPS2-06-16

Two cohorts of young women (<41y at diagnosis) with invasive breast cancer: Single center data on how demographics, tumor characteristics, therapies and 5-year survival differ when treated 2000-2005 and 2014-2019

Brechje Goots, University Hospitals Leuven, Leuven, Belgium

Presentation numberPS2-06-19

Treatment Trends in Early-Stage Breast Cancer: A Population-Based Study of Medicare Fee-For-Service Enrollees in Texas

Laura B Amin, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-06-20

Fr-popea: French real-world-data of peri-operative pembrolizumab KN522 regimen in extreme ages subgroups (70 y.o) with high-risk TNBC.

Jean Sebastien Frenel, Institut de Cancérologie de l'Ouest, Saint Herblain, France

Presentation numberPS2-06-21

Real-word utilization of the 21-gene assay for guiding treatment decisions in patients with HR+/HER2- early breast cancer in the US

Gebra Cuyun Carter, Exact Sciences, Madison, WI

Presentation numberPS2-06-22

Genomic Insights in Metastatic Invasive Lobular Carcinoma: A Real-World Study

Pegah Farrokhi, University of Minnesota, College of Pharmacy, Minneapolis, MN

Presentation numberPS2-06-23

Impact of somatic PIK3CA Mutations on clinical outcomes in HER2-Positive Breast Cancer

Nickolas Stabellini, Case Western Reserve University, Cleveland, OH

Presentation numberPS2-06-24

Global Prevalence of Prophylactic Mastectomy in Women: A Systematic Reviews and Meta-Analysis

Huynh Yen Phi, Taipei Medical University, Taipei City, Taiwan

Presentation numberPS2-06-25

Impact of RB1 Mutations on Clinical Outcomes in Metastatic Breast Cancer: A Real-World Subtype-Dependent Survival Analysis

Pegah Farrokhi, University of Minnesota, College of Pharmacy, Minneapolis, MN

Presentation numberPS2-06-26

Sociodemographic and Clinical Factors Associated with Late-Stage Breast Cancer in Young Brazilian Women: A 23-Year Nationwide Study of 52,734 Patients

Ana Carolina Pires, Oncoclinicas & CO, Rio de Janeiro, Brazil

Presentation numberPS2-06-27

Early Mortality in Young Women with Breast Cancer: Insights from 66,000 Cases in the Brazilian Public Health System (2000-2023)

Ana Carolina Pires, Oncoclinicas & CO, Rio de Janeiro, Brazil

Presentation numberPS2-06-28

Clinicogenomic and Immune Profiles of Male Breast Cancer by Race: Insights from a Large Real-World Cohort

Yara Abdou, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

Presentation numberPS2-06-29

Characteristics and Prognosis of Patients with Metachronous Contralateral Breast Cancer

Vasily Giannakeas, Women's College Hospital, Toronto, ON, Canada

Presentation numberPS2-06-30

Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with HER2-negative recurrent high-risk early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)

Tomoe Taji, Kansai Medical University, Osaka, Japan

Presentation numberPS2-07-01

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT)

Lubna N Chaudhary, Medical College of Wisconsin, Milwaukee, WI

Presentation numberPS2-07-02

Tissue-free epigenomic circulating tumor DNA (ctDNA) analysis pre- and post-surgery in early breast cancer: clinical features and prognostic utility

Arielle J Medford, Mass General Cancer Center/Harvard Medical School, Boston, MA

Presentation numberPS2-07-03

Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancer

Joyce O'Shaughnessy, Baylor University Medical Center, Texas Oncology, Dallas, TX and Sarah Cannon Research Institute, Dallas, TX

Presentation numberPS2-07-04

Time-to-progression patterns during first and second-line endocrine therapy across clinical features and liquid biopsy-defined mutational profiles in HR+/HER2- metastatic breast cancer

Lorenzo Gerratana, IRCCS CRO Aviano National Cancer Institute / University of Udine, Aviano, Italy

Presentation numberPS2-07-05

Methylation-based ctDNA Dynamics as a Biomarker for Treatment Response and Prognosis in Patients on the plasmaMATCH trial

Iseult M Browne, The Institute of Cancer Research, London, United Kingdom

Presentation numberPS2-07-06

Prevalence and dynamics of circulating tumor DNA among patients with triple-negative breast cancer undergoing preoperative systemic therapy with or without immunotherapy

Tae-Kyung Robyn Yoo, Asan Medical Center, Seoul, Korea, Republic of

Presentation numberPS2-07-07

Relationship of early ctDNA dynamics with response to inavolisib alone or in combination with endocrine therapy +/- CDK4/6 inhibitor in PIK3CA-mutated HR+, HER2- metastatic breast cancer from the first-in-human phI/Ib trial

Stephanie Hilz, Genentech, South San Francisco, CA

Presentation numberPS2-07-08

Longitudinal ctDNA Tracking in Early and Recurrent Breast Cancer Using an Ultrasensitive Structural Variant-Based Assay: An Updated Analysis from the TRACER Study

Mitchell J Elliott, Princess Margaret Cancer Centre, Toronto, ON, Canada

Presentation numberPS2-07-10

A Single Cell Peripheral Blood Immune Cell Atlas of Breast Cancer Disease States by Race reveals Differences in Peripheral Blood Immune Cell Composition and Functional Pathways

Fangyuan Chen, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS2-07-11

The improved long-term outcome in denosumab-treated postmenopausal women with early luminal breast cancer in Abcsg 18 is driven by progesterone receptor-positive tumors.

Christian F Singer, Medical University of Vienna, Vienna, Austria

Presentation numberPS2-07-12

Gut microbiome composition predicts pathologic complete response in patients with early-stage HER2-positive breast cancer receiving neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab

Alexis LeVee, UCLA David Geffen School of Medicine, Los Angeles, CA

Presentation numberPS2-07-13

Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures for patients with early breast cancer treated with endocrine therapy with or without palbociclib in the PALLAS trial (ABCSG-42, AFT-05, BIG 14-03)

Luca Malorni, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy

Presentation numberPS2-07-14

Characterization of long-term responders to first-line CDK4/6 inhibitors in HR+/HER2- advanced breast cancer

Fara Brasó-Maristany, IDIBAPS, Barcelona, Spain

Presentation numberPS2-07-15

Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC061

Justin M. Balko, Vanderbilt University Medical Center, Nashville, TN

Presentation numberPS2-07-16

Clinicogenomic characterization and ctDNA detection of ESR1 fusion positive metastatic breast cancer

Katheryn Santos, Dana-Farber Cancer Institute/Broad Institute, Boston, MA

Presentation numberPS2-07-17

Characterizing circulating tumor cell (CTC) enumeration and phenotypic profiling in blood with synchronously obtained tissue in metastatic breast cancer (MBC) in TBCRC /AURORA US

Karthik V Giridhar, Mayo Clinic Comprehensive Cancer Center, Rochester, MN

Presentation numberPS2-07-18

Prognostic effects of methylation-based HR and HER2 subtyping by liquid biopsy in ESR1 mutation-negative metastatic breast cancer 

Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, NY

Presentation numberPS2-07-20

Ki-67-guided stratification and resistance mechanism analysis of CDK4/6 inhibitor therapy following adaptiveneoadjuvant endocrine treatment in HR+/HER2− breast cancer

Yong-Sheng Wang, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

Presentation numberPS2-07-21

Tumor Necrosis Factor-related Weak Inducer of Apoptosis (TWEAK) – A Potential Biomarker for Predicting Response and Long-Term Outcomes in Early Breast Cancer Patients

Kerstin Wimmer, Medical University Vienna, Vienna, Austria

Presentation numberPS2-07-22

Serial, multi-omic, multi-analyte, liquid biopsy monitoring of metastatic lobular breast cancer to detect clinically-relevant heterogeneity and evolution

Andi K. Cani, University of Michigan, Ann Arbor, MI

Presentation numberPS2-07-23

Predictive markers of distant recurrence from randomized chemotherapy regimens for hormone receptor-positive breast cancer patient in the PACS-01 trial.

FREDERIQUE PENAULT-LLORCA, Centre Jean Perrin, CLERMONT FERRAND, France

Presentation numberPS2-07-24

Circulating tumor DNA (ctDNA) biomarker analyses of a phase 1/2 study evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)

Seth A Wander, Harvard Medical School, Boston, MA

Presentation numberPS2-07-25

Genomic biomarkers of response to ipatasertib in hormone receptor-positive, HER2-negative metastatic breast cancer

Zahra Bagheri, Harvard Medical School, Boston, MA

Presentation numberPS2-07-26

Clinical performance of Signatera Genome assay for predicting recurrence in patients with breast cancer

Wassim McHayleh, AdventHealth Cancer Institute, Orlando, FL

Presentation numberPS2-07-27

Qutils: open-source image-based infiltrating immune cell detection and outcomes in calgb 40502, calgb 40603, and calgb 40601 phase iii breast cancer clinical trials

Mark Vater, The Ohio State University, Columbus, OH

Presentation numberPS2-07-28

Immune microenvironment features of germline mutation-associated breast tumors revealed by single-molecule imaging in the Breast Cancer Family Registry

Marni B. McClure, National Cancer Institute, Bethesda, MD

Presentation numberPS2-07-29

Digital Histology Models Predict Chemotherapy Benefit in Randomized Adjuvant Trials and Real-World Cohorts

Frederick Matthew Howard, University of Chicago, Chicago, IL

Presentation numberPS2-07-30

Structural Variants in Homologous Recombination Repair/DNA Damage Response Pathways as an Alternative Mechanism of Genomic Instability in Breast Cancer

Arnaud Da Cruz Paula, i3S Instituto de Investigação e Inovação em Saúde, Porto, Portugal

Presentation numberPS2-08-01

A predictive gene signature for benefit from dose-dense adjuvant chemotherapy in patients with high-risk early breast cancer: results from the PANTHER phase III trial

Dimitrios Salgkamis, Karolinska Institutet, Stockholm, Sweden

Presentation numberPS2-08-02

Comprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer– An Exploratory Analysis of Biomarker Concordance and Co-Occurrence

Jennifer R Klemp, Caris Life Sciences, Irving, TX

Presentation numberPS2-08-03

A multi-site evaluation of the performance of the MasSpec Pen for surgical margin analysis during breast cancer surgeries

Ruth Costa, Baylor College of Medicine, Houston, TX

Presentation numberPS2-08-04

Site specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer

Dario Trapani, University of Milan, milan, Italy

Presentation numberPS2-08-05

Multimodal integration of real world genomic and clinical data for the prediction of brain metastasis development in breast cancer

Anton Safonov, Memorial Sloan Kettering Cancer Center, New York, NY

Presentation numberPS2-08-06

Biomarker analysis of patients treated with abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy from the Phase II AGAIN Study (WJOG14220B)

Meiko Nishimura, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Presentation numberPS2-08-07

Differences in Genomic Landscape Between Younger and Older Women with Advanced Breast Cancer

Nicole Casasanta, Yale Cancer Center, Yale School of Medicine, New Haven, CT

Presentation numberPS2-08-08

Comparison of anthropometric, systemic and mammary adiposity measures in patients with breast cancer.

Josephine Van Cauwenberge, Catholic University of Leuven, Leuven, Belgium

Presentation numberPS2-08-09

Baseline HER2 expression on circulating tumor cells in metastatic breast cancer

Brenno Pastò, University of Udine, Udine, Italy

Presentation numberPS2-08-10

Peripheral immune profiling during neoadjuvant HER2-targeted therapy in HER2-positive (HER2+) early breast cancer (EBC): Mass cytometry (CyTOF) analysis from the MARGOT trial

Elia Segui, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS2-08-11

Artificial Intelligence (AI)-based spatial assessment of tumor-infiltrating lymphocytes (TIL) and outcome in early HER2+ breast cancer (BC): ancillary study of the phase III adjuvant ShortHER trial.

Maria Vittoria Dieci, University of Padova, Padova, Italy

Presentation numberPS2-08-12

Age-associated divergence in breast cancer: clinical, molecular, and genomic insights from a large real-world cohort

Julia Foldi, UPMC, Pittsburgh, PA

Presentation numberPS2-08-13

Spatially resolved tumor subclones in HER2-positive breast cancer

Lucie Cervenkova, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Brussels, Belgium

Presentation numberPS2-08-14

Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer

Shipra Gandhi, Winship Cancer Institute of Emory Univeristy, Atlanta, GA

Presentation numberPS2-08-15

Characterization of Functional Estrogen Receptor (ER) Dependence via Comprehensive Epigenomic Liquid Biopsy Stratifies Endocrine Therapy (ET) Responders with Metastatic Breast Cancer (MBC)

Stefania Morganti, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS2-08-16

Validation of a multi-omic biosignature to predict locoregional recurrence risk and the benefit of adjuvant radiation therapy in women with early-stage invasive breast cancer treated with breast-conserving surgery and endocrine therapy.

G Bruce Mann, Royal Melbourne and Royal Women's Hospital, Parkville, Australia

Presentation numberPS2-08-17

Prevalence and clinical significance of exon 6 ESR1 gene fusions in advanced breast cancer after disease progression on aromatase inhibitors

Seth A. Wander, Massachusetts General Hospital Cancer Center, Boston, MA

Presentation numberPS2-08-18

Cathepsin Protease Expression and Therapeutic Outcomes to Trastuzumab Deruxtecan (T-DXd) in Metastatic Breast Cancer

Samer Alkassis, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA

Presentation numberPS2-08-19

Ki67 Spatial Heterogeneity as a Predictive and Prognostic Marker in Breast Cancer: A Spatial Image Analysis Approach

Christophe Van Berckelaer, Antwerp University Hospital (UZA), Edegem, Belgium

Presentation numberPS2-08-20

Translational analysis of cerebrospinal fluid (CSF) and plasma circulating tumor DNA (ctDNA) from breast cancer patients (pts) with leptomeningeal disease (LMD) treated with trastuzumab deruxtecan (T-DXd) in the DEBBRAH trial

Amanda Fitzpatrick, King's College London, London, United Kingdom

Presentation numberPS2-08-21

Circulating tumor DNA (ctDNA) Dynamics in Early-stage Breast Cancer Patients (pts) with Brain Metastases

Amy J. Xu, Memorial Sloan Kettering Cancer Center, New York, NY

Presentation numberPS2-08-22

Clinical Relevance of ctDNA-Guided Molecular Profiling After Progression on CDK4/6 Inhibitor plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer

Antonio Marra, European Institute of Oncology IRCCS, Milano, Italy

Presentation numberPS2-08-23

Association Between Peripheral Eosinophils and Survival Outcomes in HR+HER2- Breast Cancer: An Analysis of 15,262 Patients

Ze-Qing Li, Fudan University Shanghai Cancer Center, Shanghai, China

Presentation numberPS2-08-24

Detection of predictive mutations and HER2/neu expression from circulating tumor cells of metastatic breast cancer patients: new opportunities by analyzing high blood volumes obtained by diagnostic leukapheresis

André Franken, University Hospital Duesseldorf, Duesseldorf, Germany

Presentation numberPS2-08-25

Endocrine Sensitivity and Predicted Benefit of Extended Endocrine Therapy based on Breast Cancer Index (BCI) in BRCA1, BRCA2 and CHEK2 Pathogenic Variant Carriers with ER+/HER2- Breast Cancer

Siddhartha Yadav, Mayo Clinic, Rochester, MN

Presentation numberPS2-08-26

Pathologist- and artificial intelligence-based TILs assessment in patients with early triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: real-world evidence from a nationwide cohort

Ioannis Zerdes, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden

Presentation numberPS2-08-28

Artificial Intelligence-Based Histopathology Model Predicts Recurrence Risk in Older Patients with Early HR+/HER2− Breast Cancer: Results from the Basel University Hospital Cohort

Elena Diana Chiru, Cancer Center Baselland, Liestal, Switzerland

Presentation numberPS2-08-29

Plasma hepcidin as a prognostic biomarker in obese and non-obese patients with early breast cancer (BC): a pooled analysis of two prospective cohort studies

Evan A Cescon, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

Presentation numberPS2-09-01

Optimizing Transfer Learning for Early Prediction of Pathologic Complete Response in Breast Cancer: A Multicenter Study Using Pretreatment DCE-MRI

Kanika Bhalla, Washington university School of Medicine in st louis, St. Louis, MO

Presentation numberPS2-09-02

Neutrophil extracellular traps signature to predict pathological complete response in patients with triple negative breast cancer after neoadjuvant systemic therapy

Takeo Fujii, National Cancer Institute, Bethesda, MD

Presentation numberPS2-09-03

Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.

Pravin Kesarwani, BriaCell Therapeutics, Philadelphia, PA

Presentation numberPS2-09-04

Predicting outcomes for patients with mixed ductal/lobular carcinoma of the breast based on circulating tumor DNA positivity patterns

Julia Foldi, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA

Presentation numberPS2-09-05

Feasibility of Virtual RNA Inference from Histopathology to Identify Gene Signatures of Neoadjuvant Chemotherapy and Immune Checkpoint Inhibitor (ICI) Response in Triple-Negative Breast Cancer (TNBC)

Yuan Yuan, Cedars Sinai Medical Center, Los Angeles, CA

Presentation numberPS2-09-06

Investigating MRD Prevalence and Dynamics to Predict Exceptional Response to HER2 targeted therapy for HER2-positive Metastatic Breast Cancer

Stefania Morganti, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS2-09-08

Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database

Saranya Chumsri, Mayo Clinic, Jacksonville, FL

Presentation numberPS2-09-09

Early on-treatment PD-L1 expression and stromal tumor infiltrating lymphocytes (sTILs) refine the prediction of EFS in the NeoTRIP trial

Matteo Dugo, IRCCS Ospedale San Raffaele, Milan, Italy

Presentation numberPS2-09-10

Aneuploid-associated molecular features and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

Eo-Ryeong Lee, Fudan University Shanghai Cancer Center, Shanghai, China

Presentation numberPS2-09-11

Beyond the tumor: a CAF-Driven Gene Signature for Early Clinical Stratification of Metastasis Risk in Breast Cancer

Daniela P. Barrera, Environ, Santiago, Chile

Presentation numberPS2-09-12

Splenomegaly and response to chemo-immunotherapy in Triple-Negative Breast Cancer: Findings from MMTV-R26^Met mouse model and patients

Jean MONATTE, INSERM, CNRS, Aix-Marseille Université, Marseille, France

Presentation numberPS2-09-14

When interception needs a second chance: ctDNA dynamics in ER+/HER2- advanced breast cancer treated with 1st line CDK4/6 inhibitors – Insights from the CICLADES study

Vincent Massard, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France

Presentation numberPS2-09-15

Application of CNSigs, An R Package for the Identification of Copy Number Mutational Signatures, in Early and Advanced Breast Cancer

Shawn Striker, Ohio State University, Columbus, OH

Presentation numberPS2-09-16

Optical genome mapping and multi-modal characterization of breast tumor and organoid samples reveal structural variation and gene fusion signatures

Rahul Kumar, UPMC Hillman Cancer Center and Magee-Women’s Research Institute, University of Pittsburgh, Pittsburgh, PA

Presentation numberPS2-09-17

Comprehensive peripheral immune profiling in Triple Negative Breast Cancer (TNBC) links immune cell dynamics to therapeutic response and irAEs: insight from the IRIS Study

Letizia Negrini, University of Eastern Piedmont, Novara, Italy

Presentation numberPS2-09-18

Real-time liquid biopsy assessment in early-stage breast cancer: methylation based-ctDNA analysis and CTCs detection as potential predictors of response to neoadjuvant therapy

Caterina Gianni, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy

Presentation numberPS2-09-19

Tonsl, an immortalizing oncogene on chr.8q24.3 amplicon, confers intrinsic resistance to cdk4/6 inhibitors in breast cancer.

Harikrishna Nakshatri, Indiana University School of Medicine, Indianapolis, IN

Presentation numberPS2-09-20

Circulating Tumor DNA Dynamics and Anatomical Patterns of Relapse Following Curative Therapy in Early-Stage Breast Cancer

Daniel Stover, Ohio State University, Columbus, OH

Presentation numberPS2-09-21

Real-world clinical outcomes and genomic insights for patients with PIK3CA-mutant metastatic breast cancer following progression on CDK4/6 inhibitor therapy

Maxwell R Lloyd, Beth Israel Deaconess Medical Center, Boston, MA

Presentation numberPS2-09-22

The Impact of Breast Cancer Histology and Tumor Molecular Subtype on Nodal Positivity

Erin Elizabeth Burke, The Ohio State University, Columbus, OH

Presentation numberPS2-09-23

Preliminary Results from the NEOMET Trial: Nutritional and Exercise Interventions During Neoadjuvant Chemotherapy in Early Breast Cancer

Ida Taglialatela, University of Eastern Piedmont, Novara, Italy

Presentation numberPS2-09-24

Aurora Kinase A (AURKA) a new druggable target in ER+ Inflammatory Breast Cancer

Tanu Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-09-25

Monitoring Upregulation of PD-L1 in Cancer Associated Macrophage-Like Cells in Blood Predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

Daniel L Adams, CreatvBio, Monmouth Junction, NJ

Presentation numberPS2-09-26

Circulating microRNA and cytokine signatures associated with interstitial lung disease in patients treated with trastuzumab deruxtecan.

Manuel Alva Bianchi, Hospital 12 de Octubre, Madrid, Spain

Presentation numberPS2-09-27

Patterns of central nervous system (CNS) and leptomeningeal (LM) involvement in advanced breast cancer (BC) with invasive lobular histology: insights from a large multicenter study with a focus on estrogen receptor-positive (ER+)/HER2- disease

Federica Miglietta, University of Padova, Padova, Italy

Presentation numberPS2-09-28

Use of DiviTum^®TKa assay to assess CDK4/6 inhibitor medication compliance and drug interactions.

Mariya Rozenblit, Yale University School of Medicine, Yale Cancer Center, New Haven, CT

Presentation numberPS2-09-29

Validity of the p53 antibody DO-7 as a surrogate for predicting TP53 mutation status in breast cancer

Joshua Van Allen, University of Connecticut, Farmington, CT

Presentation numberPS2-09-30

Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model.

Mohd Mughees, UT MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-10-01

Mutational profiles from liquid biopsies in early versus late progressors treated with CDK inhibitors in 1st line metastatic breast cancer

Marie Brichard, Cliniques universitaires Saint-Luc (CUSL), Brussels, Belgium

Presentation numberPS2-10-02

Liquid Biopsy Tracking of PI3K-mTOR Residual Disease Signatures in Metastatic Breast Cancer

Sudha Rao, QIMR Berghofer Medical Research Institute, Herston, Australia

Presentation numberPS2-10-03

Impact of Circulating Tumor DNA (ctDNA) monitoring on Patient Anxiety and Clinician Decision-Making in Early-Stage Breast Cancer (PACE-ctDNA)

Devora Isseroff, Yale University, New Haven, CT

Presentation numberPS2-10-04

Tumor-infiltrating lymphocytes – a promising predictive and prognostic biomarker for optimizing neoadjuvant treatment response: a single-institution retrospective analysis

Bibiana Vertakova Krakovska, St.Elizabeth Cancer Centre, Bratislava, Slovakia

Presentation numberPS2-10-05

Association of clinicopathologic features with plasma protein expression in primary invasive breast cancer patients

Anupama Praveen Kumar, Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA

Presentation numberPS2-10-06

Proteogenomic profiling of treatment-naïve breast cancer biopsies from patients receiving neoadjuvant chemotherapy

Eric Jaehnig, Baylor College of Medicine, Houston, TX

Presentation numberPS2-10-07

Predictive Biomarkers of Response and Survival Following Treatment with the HER2-Targeted Antibody-Drug Conjugate Disitamab Vedotin in HER2-Expressing Metastatic Breast Cancer: A Proteomics-Based Study

Yun Wu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Presentation numberPS2-10-08

Quantitative measurement of HER2 and TROP2 predicts outcomes with trastuzumab deruxtecan in metastatic breast cancer

Charles J Robbins, Yale School of Medicine, New Haven, CT

Presentation numberPS2-10-09

Evaluation of spatial collagen morphometry in TNBC versus non-TNBC biopsies: a cross-sectional SHG/TPE and AI-based analysis of tumor and non-tumor regions

Kutbuddin Akbary, HistoIndex, Singapore, Singapore

Presentation numberPS2-10-10

Ten-year outcomes of Chinese early breast cancer patients with PIK3CA/AKT1 mutations: A retrospective cohort study

Ting Luo, West China Hospital, Sichuan University, China, Chengdu, China

Presentation numberPS2-10-11

Evaluating the impact of neighborhood deprivation on CDK4/6 inhibitor use, outcomes, and circulating tumor DNA (ctDNA) alterations in patients with metastatic breast cancer

Emily L. Podany, Washington University in St. Louis, St. Louis, MO

Presentation numberPS2-10-12

Perioperative minimal residual disease monitering using a tumor-informed ctDNA assay in stage II-III breast cancer

JONGSEONG AHN, IMBDx, Seoul, Korea, Republic of

Presentation numberPS2-10-13

Impact of infusion Time-of-Day of Administration (ToDA) of neoadjuvant immunochemotherapy on pathological response in patients with early Triple-negative Breast Cancer treated with KEYNOTE-522 regimen (PEMCLOCK study)

Clémentine Bouchez, Hôpital Saint Louis APHP, Faculté de médecine Paris Cité, Paris, France

Presentation numberPS2-10-14

Blood-based metabolomic profiling and transcriptomic analysis of circulating cd3⁺ t cells reveal associations with treatment response and immune activation in early breast cancer (ebc)

Veronica Martini, Azienda Ospedaliero Universitaria, Maggiore della Carità, Novara, Novara, Italy

Presentation numberPS2-10-15

Prospective evaluation of a mRNA ERBB2 score as a tool to guide HER2 status and accelerate neoadjuvant decision-making in ER-negative breast cancer

Marta Gonzalez-Rodriguez, Hospital Clínic Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain

Presentation numberPS2-10-16

Distinct Immune Landscapes in Inflammatory and Metaplastic Breast Cancer: Insights from Transcriptomic Profiling

Elyse R Lopez, The University of Texas MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-10-17

Potential of MEK Inhibition to overcome Trastuzumab deruxtecan Resistance in MAPK-Activated Triple-Negative Breast Cancer PDX Models

Adrian Gonzalez Gonzalez, Washington University in St Louis, St Louis, MO

Presentation numberPS2-10-18

Epithelial-mesenchymal transition (EMT) Signature Score of a Bulk Tumor May Not Reflect the EMT of Malignant Epithelial Cells

Yoshihisa Tokumaru, Central Japan International Medical Center, Minokamo, Japan

Presentation numberPS2-10-19

Circulating tumor DNA (ctDNA) as a strong prognostic biomarker of minimal residual disease (MRD) using a tissue-free, epigenomic assay in early-stage breast cancer

Wolfgang Janni, University Hospital Ulm, Ulm, Germany

Presentation numberPS2-10-20

Dual biomarker approach for minimal residual disease detection in early breast cancer using high-volume blood samples

Iñaki Comino-Méndez, Institute of biomedical research of Malaga (IBIMA), Malaga, Spain

Presentation numberPS2-10-21

Associations Between Circulating Tumor DNA Genomic Profiles and Serum Thymidine Kinase Patterns in Patients with Advanced, Hormone Receptor-Positive, HER2-Negative (HR+/HER-) Breast Cancer Initiating Treatment with a CDK4/6 Inhibitor (CDK4/6i)

Elena M. Michaels, Massachusetts General Hospital, Boston, MA

Presentation numberPS2-10-22

Proteomic analysis of residual disease identifies potential prognostic biomarkers of triple-negative breast cancer after neoadjuvant chemotherapy

Xi Chen, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, China

Presentation numberPS2-10-23

Circulating Tumor DNA Dynamics in Patients with Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Assessed Using an Ultrasensitive Tumor-Informed Assay

Carlos H Barcenas, University of Texas MD Anderson Cancer Center, HOUSTON, TX

Presentation numberPS2-10-24

Impact of HER2 status dynamics on fam-trastuzumab deruxtecan-nxki treatment outcomes in metastatic breast cancer: real-world insights

Yuanqing Ye, Eisai Inc., Nutley, NJ

Presentation numberPS2-10-25

Combined T and B cell signatures as prognostic biomarkers in triple-negative breast cancer (TNBC)

Shipra Gandhi, Winship Cancer Institute of Emory University, Atlanta, GA

Presentation numberPS2-10-26

Tumor genomic profiling results in breast cancer patients: A comprehensive analysis from a laboratory research registry.

Gregory A. Vidal, West Cancer Center and Research Institute, Germantown, TN

Presentation numberPS2-10-27

Unmasking Sampling Artefacts in Early Breast Cancer: Molecular Shifts Between Diagnostic and Surgical Specimens in the Absence of Therapy

Milana Arantza Bergamino Sirvén, Hospital Clinic de Barcelona, Barcelona, Spain

Presentation numberPS2-10-28

Multiomics landscape analysis and identification of diagnostic biomarkers for phyllodes tumors of the breast

Heyan Chen, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Presentation numberPS2-10-29

Tumor emboli in inflammatory breast cancer reveals macrophage-TNF-a signaling networks as targetable pathways

Pritha PAI, Duke University School of Medicine, Durham, NC

Presentation numberPS2-10-30

Tumor-associated macrophage (TAMs) and cancer-associated fibroblasts (CAFs) profiles in invasive lobular carcinoma (ILC) vs no special type (NST)

Jason Mouabbi, MD Anderson Cancer Center, Houston, TX

Presentation numberPS2-11-01

Lmtk2: a novel driver of endocrine resistance in ER+ breast cancer

Anna M Detry, Mayo Clinic, Rochester, MN

Presentation numberPS2-11-02

Chemotherapy-educated macrophages promote dormant tumor cell reactivation by shaping a pro-fibrotic niche

Dalit Barkan, University of Haifa, Haifa, Israel

Presentation numberPS2-11-03

Fish-positive circulating tumor cells persist after effective therapy in estrogen receptor positive breast cancer: insights into genomic mechanisms of endocrine resistance

Kathryn Baldwin, LSUHS Shreveport, Shreveport, LA

Presentation numberPS2-11-04

Transcriptional Plasticity in Early Evolving Endocrine Therapy Resistance

Yash N Agrawal, University of North Carolina at Chapel Hill, Chapel Hill, NC

Presentation numberPS2-11-05

Nuclear HER2-ER crosstalk in HR+/HER2+ breast cancer

Stanley Tam, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Presentation numberPS2-11-06

Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial

Tam Binh Vinh Bui, University of California San Francisco, San Francisco, CA

Presentation numberPS2-11-07

Linc00152-regulated pde4d is a mediator of drug resistance and metastasis in highly aggressive breast cancer

Ozge Saatci, Medical University of South Carolina, Charleston, SC

Presentation numberPS2-11-08

Stemness-targeted therapies to enhance the efficacy of AURKA inhibitors in endocrine resistant er+ breast cancer

ANTONINO BONAVENTURA D'ASSORO, Mayo Clinic, ROCHESTER, MN

Presentation numberPS2-11-09

Pan RTK negative regulator LRIG1 as a therapeutic target for endocrine resistance in estrogen receptor-positive breast cancer

Brittany D Jenkins, Johns Hopkins University, Baltimore, MD

Presentation numberPS2-11-10

Mct4 drives triple-negative breast cancer progression via lactate-induced histone lactylation and mapk pathway activation

Yang Peng, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Presentation numberPS2-11-11

Mechanisms of Acquired Resistance to PI3K Inhibitors in Breast Cancer: The Central Role of Autophagy

Stefania Cocco, INT IRCSS Fondazione G. Pascale, naples, Italy

Presentation numberPS2-11-12

Ccl5 and endoglin as a therapeutic target in er positive breast cancer

Kideok Jin, Albany College of Pharmacy and Health Sciences, Albany, NY

Presentation numberPS2-11-13

Resistance to tucatinib associated with hyperactive EGFR could be overcome by co-targeting HER2 and EGFR in HER2-positive breast cancer models

Fu-Tien Liao, Baylor College of Medicine, Houston, TX

Presentation numberPS2-11-14

Residual disease after trastuzumab deruxtecan treatment of HER2+ breast tumors is promoted by leucyl tRNA synthetase 2 (LARS2) in HER2-low tumor cells.

Sheheryar Kabraji, Roswell Park, Buffalo, NY

Presentation numberPS2-11-15

Etv4 mediates fgf1-induced metabolic reprogramming in obesity-driven endocrine-resistant breast cancer

Barbara Mensah Sankofi, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Presentation numberPS2-11-17

Engineered EVs-mediated miR-222 targeting PTEN/FN1 axis reverses anthracycline resistance in HER2-negative breast cancer

Wei-xian Chen, Changzhou No.2 People's Hospital, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China

Presentation numberPS2-11-18

Acetyl coA-fuels lipid storage to support triple negative breast cancer chemoresistance

Katherine E Pendleton, Baylor College of Medicine, Houston, TX

Presentation numberPS2-11-19

Intratumoral Lactobacillus iners Drives Chemoresistance in Breast Cancer: A Ferroptosis-Evasion Mechanism via NSUN2 Lactylation

Yuanxiang Lu, Henan provincial people's Hospital, Zhengzhou, China

Presentation numberPS2-11-20

Recurrent ciliary alterations under neoadjuvant selection are associated with inferior breast cancer outcomes

Julia Dory Ransohoff, Stanford University, Palo Alto, CA

Presentation numberPS2-11-21

The mechanism research on polyamine targeting ZNF133-L1CAM axis to suppress malignant progression of breast cancer

chunhua xiao, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Medical, tianjin, China

Presentation numberPS2-11-22

Understanding resistance to the SMAC mimetic birinapant in triple-negative breast cancer

Elisabeth Brown, University of Utah, Salt Lake City, UT

Presentation numberPS2-11-23

Targeting APT-2 against therapy resistance in Breast Cancer

Kanjoormana Aryan Manu, Amala Cancer Research Centre, Thrissur, India

Presentation numberPS2-11-25

Paracrine FGFR activation by stromal signals and its association with immune infiltration in breast cancer

Lise Mangiante, School of Medicine, Stanford University, Stanford, CA

Presentation numberPS2-11-27

Whole-genome doubling promotes immune evasion in TNBC by epigenetically silencing antigen presentation pathways through PRC2 activity.

Pierre Foidart, Dana-Farber Cancer Institute, Boston, MA

Presentation numberPS2-11-28

Gdc-4198, a next-generation CDK4/2 inhibitor, induces durable cell cycle arrest and overcomes CDK2-driven adaptation to CDK4 inhibition

Marc Hafner, Genentech, South San Francisco, CA

Presentation numberPS2-11-29

Deciphering the tumor microenvironment related to immune regulation in triple-negative breast cancer

Yoon Jin Cha, Gangnam Severacne Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Presentation numberPS2-11-30

Functional analysis of gedatolisib combined with fulvestrant and/or palbociclib in breast cancer cell models adapted to estrogen receptor and/or CDK4/6 inhibitors

Stefano Rossetti, Celcuity Inc., Minneapolis, MN

Presentation numberPS2-12-01

Washout Efficiency in Cancer Drug Development: A Strategy to Minimize Toxicity

Mamoru Takada, Chiba University, Chiba, Japan

Presentation numberPS2-12-02

An Innovative Postbiotic Product Based on Sequential Fermentation of L.paracasei NPB01 and L.rhamnosus GG Demonstrates Antitumor Activity against Breast Cancer

Roberto Berni Canani, University of Naples "Federico II", Naples, Italy

Presentation numberPS2-12-04

Promoter Hypermethylation-Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5-Mediated Wnt/β-Catenin Pathway Activation

Ping Wen, Chongqing University Cancer Hospital, Chongqing, China

Presentation numberPS2-12-05

Programmed death-ligand 1expression in triple negative breast cancer: insights from an African ancestry-enriched multinational cohort

Brian Stonaker, Weill Cornell Medicine, New York, NY

Presentation numberPS2-12-07

Metabolic and immune reprogramming via SCD1 inhibition enhances chemo-immunotherapy response in TNBC

Pooja P Advani, Mayo Clinic, Jacksonville, FL

Presentation numberPS2-12-08

Obi‑201: a bispecific trop2 × her2 antibody-drug conjugate to expand therapeutic reach beyond her2-low limitations

Chi-Huan Lu, OBI Pharma, Inc., Taipei, Taiwan

Presentation numberPS2-12-09

Global expression of small DNA damage-associated RNAs (sdRNAs) in breast cancers

Jennifer M Rosenbluth, University of California, San Francisco, San Francisco, CA

Presentation numberPS2-12-10

Mediterranean Diet and Breast Cancer Biology: Novel Insights into the Role of Extracellular Vesicles

Luca Gelsomino, University of Calabria, Rende (Cs), Italy

Presentation numberPS2-12-11

Tgfβ-associated transcription factors induce metabolic and chromatin remodeling in breast cancer cells

Mohamad Moustafa Ali, Uppsala University, Uppsala, Sweden

Presentation numberPS2-12-12

Targeting RNA binding protein-deficiency associated neoepitopes for triple negative breast cancers

Michael Lee, Baylor College of Medicine, Houston, TX

Presentation numberPS2-12-13

Breast Cancer Mutation Detection via Liquid Biopsy Using cfDNA from 50 mL Urine Samples

Nafiseh Jafari, nRichDX, Irvine, CA

Presentation numberPS2-12-14

Nuclear AGO1 Drives Estrogen-Responsive Enhancer Activity and Is Associated with Poor Relapse-Free Survival in Premenopausal Breast Cancer

Angela Lara Montero, Institute of Physiology, Molecular Biology and Neurosciences., Buenos Aires, Argentina

Presentation numberPS2-12-15

Glucocorticoid receptor activation leads to remodeling of the chromatin landscape in infiltrating lobular carcinoma cells and changes in estrogen receptor-mediated gene expression

Amanda Briceno, UT Southwestern Medical Center, Dallas, TX

Presentation numberPS2-12-16

Tp53 mutant tnbc overexpresses serine biosynthesis genes psat1 and phgdh and may demonstrate vulnerability to dietary glycine supplementation

Jules Cohen, Stony Brook Cancer Center, Stony Brook, NY

Presentation numberPS2-12-18

The role of MARCKS in inflammation in inflammatory breast cancer using in vitro and in silico studies

Maroua Manai, Pasteur Institute of Tunis, Tunis, Tunisia

Presentation numberPS2-12-19

Single cell mutational fingerprints and the viral culprits: uncovering APOBEC3 dysregulation in breast cancer

Jake D Lehle, Texas Biomedical Research Institute, San Antonio, TX

Presentation numberPS2-12-20

The Oncogenic Role of MitoNEET in Breast Cancer

Connor Kent, Louisiana State University Health Sciences Center, New Orleans, LA

Presentation numberPS2-12-21

Deubiquitinase USP16 stabilizes CYBA expression and promotes progression and chemoresistance in triple-negative breast cancer chemoresistance in triple-negative breast cancer

Ningning Zhang, Chongqing University Cancer Hospital, Chongqing, China

Presentation numberPS2-12-22

The Molecular Mechanism of PRAK Regulating DNA Damage Repair and Its Role in Breast Cancer

Liu Jingjing, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

Presentation numberPS2-12-23

Persistent Morphological and DNA Damage Changes Following Ultra-Low Dose and Dose Rate Radiation in a 3D Human Mammary Organoid Model with Wild-Type and p16-Mutant Isogenic Lines

Janice Pluth, UNLV, Las Vegas, NV

Presentation numberPS2-12-24

Ifitm1 influences natural killer cell-mediated cytotoxicity by modulation of hla-class i expression in triple-negative breast cancer cells

Hye Sung Won, Uijeongbu St Mary's Hospital, College of Medicine, The Catholic University of Korea, Gyeonggi-do, Korea, Republic of

Presentation numberPS2-12-25

Edil3/del-1-induced phosphorylation of ampkβ facilitates progression and correlates with poor prognosis in triple-negative breast cancer

Lee Soo Jung, Kyungpook national university chigok hospital, Daegu, Korea, Republic of

Presentation numberPS2-12-26

Tp53-dependent and -independent transcriptomic responses to pan-14-3-3 inhibition under dna damage in breast cancer cells

EMIKO HIRAOKA, Hiroshima Prefectural Hospital, Hiroshima, Japan

Presentation numberPS2-12-27

Differential Responses to the Senolytic Activities of Navitoclax and Venetoclax in Murine Models of Triple Negative Breast Cancer

Moureq Alotaibi, King Saud University, Riyadh, Saudi Arabia

Presentation numberPS2-12-28

Marveld1 expression in breast cancer and the impact on the aggressive nature of breast cancer cells

Hong Yu Xiang, Cardiff University, Cardiff, United Kingdom

Presentation numberPS2-12-29

Helz-mediated r-loop resolution orchestrates brca2-dependent dna repair in hormone-driven breast cancers

Wenjing Li, UTHSCSA, San Antonio, TX

Presentation numberPS2-12-30

Distribution and prognostic significance of recurrence score by histologic sub-type among women with early-stage hormone receptor-positive invasive breast cancer

MacKenzie Mayo, Karmanos Cancer Institute, Detroit, MI

Presentation numberPS2-05-02

Feasibility of Tailored Axillary Surgery (TAS) in Patients with Clinically Node-Positive Breast Cancer in the Upfront Surgery Setting: Results of a Prospective, Single-Arm, Multicenter Phase II Trial

Kaori Terata, Akita University Hospital, Akita, Japan

Presentation numberPS2-05-12

Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Clinically Node-Negative Early Breast Cancer: Feasibility and Safety in Triple-Negative and HER2-Positive Breast Cancer Subtypes

Qijun Zheng, Peking University Cancer Hospital & Institute, Peking, China

Presentation numberPS2-05-14

Omitting Sentinel Lymph Node Dissection After Neoadjuvant Treatment in Early Breast Cancer: Interim Results from the VENUS Randomized Clinical Trial

Giuliano M Duarte, State University of Campinas – UNICAMP, CAMPINAS, Brazil

Presentation numberPS2-05-15

Outcome of De-Escalation of Axillary Surgery in Locally Advanced Breast Cancer Patients

Brijesh Kumar Singh, All India Institute Of Medical Sciences New Delhi, New Delhi, India

Presentation numberPS2-05-27

Omission of Axillary Surgery in Early Breast Cancer with Negative Lymph Nodes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Giuliano M Duarte, State University of Campinas – UNICAMP, CAMPINAS, Brazil

Presentation numberPS2-05-29

Feasibility and outcomes of premastectomy radiation therapy in locally advanced breast cancer

Risa Kiernan, Memorial Sloan Kettering Cancer Center, New York, NY

Presentation numberPS2-05-30

Long-term Outcome Prediction with Residual Cancer Burden (RCB) post Neo-adjuvant Chemotherapy in Breast Cancer patients – LOPNeoRCB: An ambispective study

Brijesh Kumar Singh, All India Institute Of Medical Sciences New Delhi, New Delhi, India

Presentation numberPS2-06-07

The Necessity of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ Patients: a Retrospective Analysis of a Single Institute in Taiwan

Yu-Hsuan Chen, Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan

Presentation numberPS2-06-17

Olaparib Use and gBRCA Testing among HER2-Negative Early-Stage Breast Cancer Patients in the United States Community Oncology Setting

Kathryn Mishkin, Merck & Co., Rahway, NJ, MD

Presentation numberPS2-07-19

Proteomic subtyping of stage II/III TNBC from the I-SPY2 TRIAL reveals a druggable steroid hormone receptor signature (SRS) that is associated with poor outcome and enriched in non-pCR patients’ residual disease

Julia Wulfkuhle, George Mason University, Manassas, VA

Presentation numberPS2-11-24

Collagen prolyl 4-hydroxylase promotes breast cancer endocrine resistance via regulation cellular stress

Gaofeng Xiong, The Ohio State Univeristy, Columbus, OH

Presentation numberPS2-09-07

Ultra-sensitive Molecular Residual Disease Detection in Breast Cancer Using Whole-Genome Sequencing-Based Personalized ctDNA Panels: Preliminary Results from the MONSTAR-SCREEN-3 Project

Yoichi Naito, National Cancer Center Hospital East, Kashiwa, Japan

Presentation numberPS2-11-26

Oncogenic er alpha as an rna-binding protein controls mrna stability and epitranscriptome of breast cancer

Nimmy Mohan, University of California, San Francisco, San Francisco, CA

Presentation numberPS2-12-06

BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia

Kerstin W Sinkevicius, BBOT, South San Francisco, CA

Presentation numberPS2-13-04

Glucocorticoids promote metabolic reprogramming that underlies enhanced proliferation of breast cancer stem and progenitor cells under conditions of chronic stress

Jonathan Dowgielewicz, The University of Chicago, Chicago, IL

Presentation numberPS2-13-06

The M1C/MYC Axis Reprograms Alternative Splicing Networks in Triple Negative Breast Cancer

Atrayee Bhattacharya, University of Texas Health Science Center at Tyler, Tyler, TX

Presentation numberPS2-13-07

Disrupted epithelial differentiation and mitochondrial remodeling as early events in BRCA-associated carcinogenesis

Quentin Chartreux, UTSA Health Science Center, San Antonio, TX

Presentation numberPS2-13-10

Impact of Dose Intensity on Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer

Shaheed K AlHumiued, Eastern health cluster, Dammam, Saudi Arabia

Presentation numberPS2-13-11

Enhancing Nurse Competence in Malignant Wound Management: A Multicenter Assessment of Knowledge, Attitudes, and Practices in Integrated Care Settings

Liang Xu, Peking University Cancer Hospital & Institute, Beijing, China